Drug Discovery & Pharmaceuticals

RSS

High affinity antibodies isolated to safely target Claudin 6-positive tumors

Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) antibody CTIM-76 being developed for cancer therapy with Context Therapeutics.

6 Jan 2023

Insilico Medicine launches a 6th generation Intelligent Robotics Drug Discovery Laboratory

Insilico Medicine, a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life Star – a 6th generation Intelligent Robotics Drug Discovery Laboratory – in Suzhou BioBAY Industrial Park on Dec. 29.

5 Jan 2023

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.

From PhoreMost 5 Jan 2023

Technical advances expand the application of mass spectrometry imaging in pharmaceutical research

Announcing a new publication for Acta Materia Medica journal. Mass spectrometry imaging (MSI) has been shown to be a valuable tool through nearly every stage of the preclinical drug research and development (R&D) pipeline, and even to the early phase of clinical pharmaceutical evaluation.

3 Jan 2023

Insilico announces nomination of preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy

Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company's drug discovery team has nominated a preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy utilizing its end-to-end Pharma.AI platform.

27 Dec 2022

Researchers present a new strategy for self-adjuvanting vaccine development

This new article publication from Acta Pharmaceutica Sinica B, discusses a fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development.

23 Dec 2022

Research serves as a platform to identify therapeutic drugs for schizophrenia

Inflammation and overactivation of the immune system in the brain can cause loss of synapses and the death of neurons, leading to neurodegenerative and psychiatric diseases.

22 Dec 2022

MGI’s DNBSEQ-T7* facilitates ultra-deep sequencing of high-complexity metagenomic samples

Thanks to high-throughput sequencing technologies, shotgun metagenomic methods were made possible and had effectively transformed microbiology. Today, advances in both short- and long-read technologies are overcoming many of the previous challenges affecting metagenomic profiling, especially of highly complex samples and environment.

From MGI 20 Dec 2022

Newly designed antibiotic effective against multidrug-resistant bacteria

Researchers have designed and synthesized analogs of a new antibiotic that is effective against multidrug-resistant bacteria, opening a new front in the fight against these infections.

20 Dec 2022

Scientists suggest vibrational spectroscopy and nuclear magnetic resonance to evaluate drug concentrations

Scientists at Baltic Federal University have suggested evaluating concentration and chemical composition of drugs by means of vibrational spectroscopy and nuclear magnetic resonance instead of conventional complex approaches.

20 Dec 2022

Decoding nucleic acid-based drugs and vaccines through SEC-SLS analysis

In this interview, Malvern Panalytical’s Product Technical Specialist, Stefan Cairns, discusses how SEC-SLS can be used to understand MRNA vector composition by referencing his latest publication.

From Malvern Panalytical 19 Dec 2022

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative role within the Company’s Scientific Advisory Board.

From CN-Bio 19 Dec 2022

Drug Discovery & Pharmaceuticals

High affinity antibodies isolated to safely target Claudin 6-positive tumors

Insilico Medicine launches a 6th generation Intelligent Robotics Drug Discovery Laboratory

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

Technical advances expand the application of mass spectrometry imaging in pharmaceutical research

Insilico announces nomination of preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy

Researchers present a new strategy for self-adjuvanting vaccine development

Research serves as a platform to identify therapeutic drugs for schizophrenia

MGI’s DNBSEQ-T7* facilitates ultra-deep sequencing of high-complexity metagenomic samples

Newly designed antibiotic effective against multidrug-resistant bacteria

Scientists suggest vibrational spectroscopy and nuclear magnetic resonance to evaluate drug concentrations

Decoding nucleic acid-based drugs and vaccines through SEC-SLS analysis

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

Mucosal DNA vaccine provides protection against lethal SARS-CoV-2 in mice

Natural substances show great therapeutic potential to inhibit influenza viruses

Radical project aims to develop a new method for commercial production of anti-microbial peptides

Study provides new insights for the future development of oral insulin pill

Structural studies pave the way for cancer drugs that could target only mutated versions

Researchers design novel compounds with potential as drug treatments for COVID-19

Discovery of cellular uptake pathway for larger molecules can be harnessed to create new drugs

Discovery of ’raspberry-shaped’ nanoparticle offers a way to enhance the effectiveness of existing drugs

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest Life Science News